Potent and Selective EphA4 Agonists for the Treatment of ALS
Bainan Wu1, Surya K De2, Anna Kulinich2
1Sanford-Burnham-Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
Abstract:
Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease that affects motor neurons. Recent studies identified the receptor tyrosine kinase EphA4 as a disease-modifying gene that is critical for the progression of motor neuron degeneration. We report on the design and characterization of a family of EphA4 targeting agents that bind to its ligand binding domain with nanomolar affinity. The molecules exhibit excellent selectivity and display efficacy in a SOD1 mutant mouse model of ALS. Interestingly, the molecules appear to act as agonists for the receptor in certain surrogate cellular assays. While the exact mechanisms responsible for the therapeutic effect of the new agonists remain to be elucidated, we believe that the described agent represents both an invaluable pharmacological tool to further decipher the role of the EphA4 in ALS and potentially other human diseases, and a significant stepping stone for the development of novel treatments.
Insights
Researchers developed novel agents targeting EphA4 for amyotrophic lateral sclerosis (ALS). These agents show efficacy in mouse models, offering a potential new therapeutic avenue for ALS and other neurodegenerative diseases.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease.
- The receptor tyrosine kinase EphA4 is implicated in motor neuron degeneration in ALS.
Purpose of the Study:
- To design and characterize novel EphA4-targeting agents.
- To evaluate the therapeutic potential of these agents in an ALS mouse model.
Main Methods:
- Design and synthesis of EphA4-targeting molecules.
- Affinity and selectivity characterization.
- In vivo efficacy testing in a SOD1 mutant mouse model of ALS.
- Cellular assays to investigate receptor agonism.
Main Results:
- Developed a family of EphA4 ligands with nanomolar affinity and high selectivity.
- Demonstrated therapeutic efficacy in a SOD1 mutant mouse model of ALS.
- Observed potential agonist activity in cellular assays.
Conclusions:
- The novel EphA4-targeting agents are promising pharmacological tools for studying ALS.
- These agents represent a potential therapeutic strategy for ALS and other human diseases.
- Further research is needed to elucidate the precise mechanisms of action.
Related Concept Videos
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
01:22Alzheimer's Disease: Treatment
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...